VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Core Viewpoint - VolitionRx Limited has announced definitive agreements for the purchase and sale of common stock, aiming to raise approximately $1.21 million in gross proceeds, with potential additional proceeds of about $1.3 million from warrants if fully exercised [1][3]. Group 1: Stock Offering Details - The company will sell 156,250 shares of common stock to insiders at $0.64 per share, and 1,734,375 shares along with warrants to other existing stockholders at the same price [1][2]. - Each warrant has an exercise price of $0.768, is immediately exercisable, and expires five years from the issuance date [1][2]. Group 2: Financial Implications - The total gross proceeds from the offering are expected to be $1.21 million before expenses, with an additional potential of $1.3 million from the exercise of warrants [3]. - The net proceeds will be utilized for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions [3]. Group 3: Regulatory Information - The offering is conducted under a shelf registration statement filed with the SEC, and the related prospectus will be available on the SEC's website [4]. Group 4: Company Overview - VolitionRx is a multinational company focused on advancing epigenetics, aiming to improve early detection and monitoring of diseases, including cancers and conditions related to NETosis [6][7]. - The company's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [8].